Predicting diabetic retinopathy progression

Article

A diabetic retinopathy (DR) progression biomarker software has been developed with the research institute AIBILI (Association for Biomedical Research and Innovation in Light and Image) and Critical Health. The RetmarkerDR is able to calculate and provide important ratios regarding Microaneurysm Turnover (formation and disappearance rates) which are key indicators of progression of retinal diseases like Diabetic Retinopathy.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.